Janssen Inc. Announces Health Canada Approval of TREMFYA™ (guselkumab) for the Treatment of Adult Moderate to Severe Plaque Psoriasis

Wednesday, November 15, 2017 Tropical Disease News
Email Print This Page Comment bookmark
Font : A-A+

_________________________

1 TREMFYA™ Product Monograph. Janssen Inc. November 10, 2017.

2 Bachelez H. Interleukin 23 inhibitors for psoriasis: not just another number. Lancet 2017;390(10091):208-210.

3 Blauvelt, A et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial. Journal of the American Academy of Dermatology. 2017;76:405-417.

4 Reich, K et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial. Journal of the American Academy of Dermatology. 2017;76:418-431.

5 Canadian Dermatology Association. https://dermatology.ca/public-patients/skin/psoriasis/ (Accessed October 26, 2017).

6 Rapp, S.R. et al. Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology. 1999;41:401-407.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store